Home Tags Site-specific conjugation technology

Tag: site-specific conjugation technology

Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates (ADCs) using Catalent's proprietary SMARTag®...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...

Eisai’s Subsidiary Morphotek Launches ADC Services

Using its proprietary REsidue-SPEcific Conjugation Technology™, also known as  RESPECT™, combined with the company's eribulin-linker toxin platforms, Morphotek, a subsidiary of Eisai, confirmed the...